Contingency management reduces drug-related human immunodeficiency virus risk behaviors in cocaine-abusing methadone patients.
OBJECTIVE
Contingency management (CM) is efficacious in reducing drug use. This study examined whether CM also reduces human immunodeficiency virus (HIV) risk behaviors and if these effects are mediated by longest duration of abstinence achieved during treatment.


METHODS
Data were analyzed from a subset of participants in a combined data set of three published randomized controlled trials of CM treatments.


METHODS
A community-based methadone maintenance clinic.


METHODS
One-hundred and sixty-five cocaine-abusing methadone maintenance patients.


METHODS
Participants received either standard methadone treatment or standard methadone treatment with CM for 3 months.


METHODS
The HIV Risk Behavior Scale (HRBS) was administered prior to randomization to a study condition and 3 months after the study treatments ended. The primary objective indicator of drug use was longest duration of cocaine and opioid abstinence achieved during treatment.


RESULTS
Relative to those assigned to standard care, participants receiving CM significantly decreased overall HIV risk behaviors and injection drug use risk behaviors. CM participants also achieved longer durations of consecutive cocaine and opioid abstinence during treatment. Duration of abstinence achieved mediated the relationship between treatment condition and HRBS difference scores.


CONCLUSIONS
These results suggest that CM treatment reduces HIV drug use risk behaviors in cocaine-abusing methadone maintenance patients.
Hanson
Tressa
T
University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3944, USA.
Alessi
Sheila M
SM
Petry
Nancy M
NM
D000328:Adult; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D001521:Behavior Therapy / Q000379:methods*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D016485:Needle Sharing / Q000009:adverse effects; D009293:Opioid-Related Disorders / Q000150:complications* / Q000534:rehabilitation; D012309:Risk-Taking; D012725:Sexual Behavior / Q000523:psychology*; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D008691:Methadone